Fact-checked by Grok 2 weeks ago

Glanders

Glanders is a contagious, zoonotic bacterial disease caused by , a gram-negative, nonmotile, aerobic that primarily infects equids such as , donkeys, and mules, leading to suppurative , abscess formation in the lungs, , and lymph nodes, with case fatality rates approaching 95% in untreated animals and 50% in humans. The pathogen is an incapable of free-living survival outside hosts, transmitted through direct contact with infected nasal secretions, from ulcers, or contaminated fomites, and in humans via cutaneous , of aerosols, or , often manifesting as acute septicemia or chronic granulomatous lesions. Historically recognized since antiquity—described by around 425 BC as a wasting disease of —glanders has caused significant equine mortality in campaigns and civilian herds, prompting eradication efforts through serological testing and that succeeded in and by the mid-20th century, though sporadic outbreaks persist in , , and the due to inadequate surveillance and cross-border animal movement. In humans, infections are rare but severe, with no licensed available and relying on prolonged antibiotics like sulfadiazine or ceftazidime, complicated by the bacterium's intrinsic and potential as a Category B agent due to its stability in aerosols and historical weaponization attempts during . Control remains challenging in endemic regions, where molecular typing reveals ongoing circulation among equids without spillover to humans in recent outbreaks.

Etiology and Microbiology

Causative Agent

Burkholderia mallei is the sole causative agent of glanders, classified as a Gram-negative, non-motile, aerobic within the Burkholderiaceae family. As an , it has undergone genomic reduction and adaptation primarily to equids, including , donkeys, and mules, enabling efficient intracellular survival and zoonotic spillover to humans through close contact. The bacterium's genome consists of two circular chromosomes totaling about 5.8 million base pairs, with no plasmids, fostering high genetic stability that limits rapid evolution and supports consistent virulence across strains. Key features enabling persistence include type VI secretion systems for host cell invasion and efflux pumps that confer resistance to multiple antibiotics, allowing chronic infections and carrier states in mammalian hosts. B. mallei is designated a Category B select agent by the CDC, reflecting its environmental durability in certain conditions, resistance to select disinfectants, and potential for weaponization due to these traits.

Pathogenic Mechanisms

Burkholderia mallei, the causative agent of glanders, invades host tissues primarily through adherence to epithelial cells mediated by type IV pili, such as PilA, and autotransporter adhesins like BpaC, which facilitate initial attachment at mucosal surfaces or skin abrasions. Following adhesion, the bacterium employs its (T3SS) effectors, including BipC, to promote phagosomal escape within macrophages, enabling intracellular replication and evasion of lysosomal degradation. The (CPS) further contributes to anti-phagocytic activity by modulating complement deposition and protecting against innate immune clearance, promoting persistence and the formation of suppurative abscesses and granulomatous lesions through chronic and . Intracellular survival is bolstered by type VI secretion system (T6SS) components, such as Hcp1 and VgrG5, which facilitate multinucleated formation and intercellular spread via polymerization, allowing dissemination from primary sites. Siderophore-mediated iron acquisition systems enhance uptake in iron-limited host environments, supporting bacterial and during systemic spread. Secreted effectors from T3SS and T6SS, functioning analogously to exotoxins, disrupt host signaling pathways, including ubiquitination and rearrangement, via proteins like BMAA0728 and BMAA1865, leading to endothelial cell damage and thrombi formation that exacerbate tissue destruction. These mechanisms culminate in bacteremia, with dissemination to lymph nodes, lungs, and , precipitating septicemia and multi-organ failure; in acute septicemic cases, untreated mortality reaches 95%, attributable to overwhelming bacterial replication and inflammatory collapse. Empirical studies in murine models confirm that disruptions in these pathways, such as T3SS or novel host-interacting proteins, significantly attenuate , underscoring their causal role in .

Clinical Manifestations

In Equids

In equids, including , donkeys, and mules, glanders typically presents in nasal, pulmonary, or cutaneous (farcy) forms, which may occur simultaneously depending on the site of initial and the host's . The nasal form features inflammatory nodules and ulcers in the and , accompanied by serous to mucopurulent, yellowish-green , epistaxis, and respiratory distress. Pulmonary involvement manifests as pyrexia, , dyspnea, and multifocal nodular lesions in the lungs, often leading to and . The cutaneous form, or farcy, is predominantly chronic and characterized by , with firm, chain-like nodules progressing to suppurative ulcers along lymphatic channels, especially in the and ventral ; these lesions may rupture and form stellate scars. In horses, glanders generally follows a subacute to chronic course with intermittent fever and vague signs, whereas donkeys and mules more frequently exhibit acute, rapidly fatal septicemia with high fever, anorexia, and widespread dissemination. Latent carriers, particularly in chronic equine cases, can shed intermittently without overt symptoms. Untreated acute glanders in equids carries fatality rates of 90–95% or higher, especially in pulmonary or septicemic presentations, with death often occurring within weeks due to overwhelming bacterial dissemination. In endemic regions like , where glanders persists despite control efforts, veterinary outbreaks exhibit high morbidity, with annual case reports across multiple states prompting mandatory , prolonged quarantines, and depopulation of affected herds. These events inflict severe economic losses on equine-dependent sectors, including industries, through direct animal losses, restricted , and diminished productivity in and . In communities reliant on draft equids, such as brick kilns in parts of , outbreaks exacerbate by halving seasonal earnings from affected animals and necessitating costly replacements.

In Humans

Glanders primarily affects through zoonotic transmission from infected equids, posing an to veterinarians, horse trainers, farriers, and laboratory workers handling Burkholderia mallei-contaminated materials. Exposure occurs via cutaneous abrasions, of aerosols, or mucosal with infected secretions, leading to localized or disseminated infection. Human cases are exceedingly rare, with fewer than 20 laboratory-confirmed incidents reported globally since 2000, underscoring the disease's low incidence despite its potential severity. Cutaneous glanders manifests as painful nodules or ulcers at the exposure site, often accompanied by regional and , progressing to formation if untreated. Systemic forms involve pneumonic symptoms such as fever exceeding 39°C (102°F), chills, , , and , or septicemic dissemination with myalgias, , and multi-organ es. The acute ranges from 1 to 14 days post-exposure, correlating with high bacterial inoculum, whereas chronic presentations may emerge after weeks to months, featuring , , and recurrent cutaneous lesions. A recent case in 2024 involved a 73-year-old male from northeastern hospitalized with fever, respiratory distress, and systemic symptoms attributable to B. mallei infection, highlighting ongoing risks in regions with enzootic equine glanders. While clinical features overlap with —caused by the environmentally acquired Burkholderia pseudomallei—glanders lacks a free-living and is confined to direct equine-to-human jumps, with human-to-human spread undocumented outside rare autopsy or procedural contexts. Untreated mortality approaches 95% in septicemic cases, emphasizing the pathogen's virulence in susceptible hosts.

Acute vs. Chronic Forms

The acute form of glanders manifests with rapid progression following high-dose exposure or inhalation of , leading to systemic , high fever exceeding 40°C, severe , and nodular abscesses in the lungs and viscera, often culminating in death within 7–10 days in untreated cases. This fulminant course correlates with overwhelming bacterial loads that evade initial host defenses, as lower immunity or intense aerosol challenge bypasses localized containment, driving unchecked replication and toxemia. In contrast, the chronic form arises from partial resistance or lower exposure doses, resulting in protracted with intermittent formation in subcutaneous tissues, nodes, and mucosal surfaces, alongside periods of where clinical signs remit. Such dynamics foster states, particularly in equids like horses, where persist intracellularly in macrophages, enabling sporadic shedding via nasal discharge or pus without overt illness, thus sustaining environmental reservoirs and facilitating undetected zoonotic or lateral transmission. Historical outbreaks, such as those in during the early , demonstrated chronic persistence in up to 50% of surviving equids, underscoring how immune-mediated prolongs infectivity over months to years.
AspectAcute FormChronic Form
Incubation Period1–14 daysUp to 12 weeks, with latency periods
Primary DriversHigh exposure dose, inhalation route, low host immunityModerate dose, partial immunity allowing bacterial dormancy
Key PathologyRapid sepsis, pulmonary nodules, high mortality (>95% untreated)Recurrent abscesses, carrier state, intermittent dissemination
Epidemiologic RoleExplosive outbreaks but self-limiting in hostsPerpetual reservoirs via subclinical shedding, evading detection

Transmission and Epidemiology

Modes of Spread

Glanders spreads primarily among equids through direct contact with infected nasal discharges or purulent exudates from skin lesions, allowing Burkholderia mallei to enter via mucous membranes of the or abraded skin. Venereal transmission occurs during , particularly in stallions and mares, via mucosal contact with genital secretions. Aerosol transmission via of respiratory droplets from coughing infected animals contributes to nasal glanders, the most common form in horses. Indirect spread facilitates outbreaks on farms through contaminated fomites such as harnesses, feed troughs, or grooming tools harboring the bacterium from exudates. B. mallei persists in moist environments, surviving up to two months in water and three months in decomposing organic matter like manure, enabling ingestion from tainted feed or water sources. Zoonotic transmission to humans occurs via close contact with infected equids, with the bacterium entering through cutaneous abrasions, conjunctivae, or inhalation of infectious aerosols during handling of nasal pus or ulcers. Human-to-human spread is rare outside laboratory settings, documented only through direct contact with cutaneous secretions or respiratory droplets from active cases. No natural arthropod vectors have been confirmed for B. mallei, distinguishing it from environmental pathogens like Burkholderia pseudomallei.

Global Distribution and Recent Outbreaks

Glanders was eradicated from the in 1934 through systematic testing, culling of infected equids, and stringent import controls, with similar successes achieved in and by the early 20th century via comparable measures. The disease persists as endemic in limited regions, primarily parts of including , , and ; portions of and the ; and , especially , where it affects equine populations annually and resists full control. Sporadic occurrences are reported elsewhere in , , and the , often linked to gaps in veterinary infrastructure. In , glanders re-emerged around 2000 after decades of absence, with 697 affected holdings documented from 2005 to 2016, concentrated in the northeast where spatiotemporal analyses revealed clustered outbreaks through 2022 in states such as and . These events prompted the of hundreds of equids, including 623 between 2013 and 2015, disrupting local equine industries and . In , outbreaks among equids have been recorded in recent years in (with high prevalence in ), Iran, , , and , where initial cases surfaced in 2022 amid inadequate prior surveillance. Factors driving these patterns include informal cross-border animal trade, insufficient testing resources, and incomplete enforcement in resource-limited settings. Human infections remain rare but underscore zoonotic risks in endemic zones; a confirmed case occurred in 2024 involving a 73-year-old man in northeast hospitalized for severe due to , highlighting direct transmission from infected equids. Conversely, achieved official recognition as glanders-free from the in September 2025, following comprehensive surveillance and elimination of donkey reservoirs. Ongoing challenges in and stem from persistent circulation in working equids and enforcement hurdles, perpetuating annual case burdens despite international reporting requirements.

Diagnosis

Clinical Evaluation

Clinical evaluation of glanders in equids begins with assessment of respiratory and cutaneous signs, including purulent or sanguinous nasal discharge, often yellow-green and originating from one or both nostrils, accompanied by ulceration of the nasal mucosa. Submandibular lymphadenopathy, progressing to abscessation, is a key indicator, alongside intermittent fever exceeding 39.5°C and progressive weight loss. In the farcy form, nodular swellings along lymphatic vessels on the legs, flanks, or neck evolve into suppurating ulcers with thick, honey-like exudate, distinguishing localized lesions from more diffuse involvement. Acute presentations in donkeys and mules feature high fever, dyspnea, and rapid systemic decline, while horses more commonly exhibit chronic, relapsing signs with cough and exercise intolerance. In humans, initial symptoms typically include fever above 38.5°C with chills, myalgias, , and , followed by and cutaneous nodules that ulcerate, particularly in exposed areas or along lymphatics. Pulmonary involvement manifests as respiratory distress, productive cough with bloody , and pleuritic pain, signaling progression beyond localized . Septicemic forms present with rapid onset of , , and multi-organ dysfunction, necessitating urgent suspicion in those with occupational exposure to equids. Differentiation from strangles relies on glanders' tendency toward systemic dissemination, with pulmonary abscesses and farcy lesions absent in the former's primarily lymph node-centric suppuration. Unlike , which shares nodular pulmonary patterns but arises from environmental exposure and chronic granulomatous progression, glanders in equids advances to acute, ulcerative without free-living reservoir history. Red flags in at-risk equids include purulent nasal discharge persisting beyond 7-10 days and exceeding typical nutritional deficits, prompting isolation pending confirmation. Early detection hinges on these observable thresholds, as chronic carriers may show subclinical signs until stress exacerbates manifestations.

Laboratory Techniques

Laboratory diagnosis of glanders relies on culture, molecular detection, and serological assays to confirm infection with . Isolation of the bacterium from clinical specimens such as , nasal swabs, or biopsies requires onto selective , including glycerol-based or specialized formulations like Burkholderia mallei (BM ), which enhances recovery while suppressing contaminants. Confirmation involves biochemical tests assessing traits such as positivity, activity, reduction, and non-motility, distinguishing B. mallei from closely related species like . All manipulations of suspect cultures demand Biosafety Level 3 (BSL-3) containment due to the organism's aerosolization potential and high infectivity via inhalation or routes. Molecular methods, particularly (PCR) targeting B. mallei-specific genes such as those encoding type IV pilin or intracellular protein BimA, offer rapid detection with high specificity but variable sensitivity. These assays detect bacterial DNA in clinical samples, yet false negatives occur frequently in early acute or chronic stages due to low bacterial loads or genomic variants, as observed in Kuwaiti strains evading certain primers. Modified PCR protocols can improve sensitivity when combined with culture, though resource-limited settings often lack the equipment and expertise, relying instead on less precise alternatives. Serological tests, including complement fixation test (CFT) and enzyme-linked immunosorbent assay (ELISA) using antigens like mallein or recombinant BimA, detect antibodies but suffer from cross-reactivity with environmental Burkholderia species and false negatives in subclinical infections. CFT, the World Organisation for Animal Health (WOAH)-endorsed standard, exhibits diagnostic sensitivity around 80-90% in proven cases but requires paired sera for accuracy, complicating field use. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) enables rapid identification of B. mallei isolates with reported approaching 100% when databases include relevant spectra, outperforming traditional biochemicals in speed. However, initial culture remains prerequisite, and misidentification risks persist without expanded spectral libraries for atypical strains. In fatal cases, postmortem examination via and culture from organs like lungs or provides definitive confirmation, circumventing antemortem diagnostic pitfalls. Overall, no single test achieves perfect ; integrated approaches mitigate false negatives, particularly in chronic glanders where bacterial persistence is erratic. Limitations in low-resource environments—such as absent BSL-3 facilities or capabilities—exacerbate underdiagnosis, potentially delaying outbreak control.

and

Antimicrobial Regimens

The primary antimicrobial regimen for acute glanders in humans consists of an initial intensive phase using intravenous antibiotics such as ceftazidime or a (e.g., or imipenem), often combined with trimethoprim-sulfamethoxazole (TMP-SMX), to address rapidly disseminating . This approach targets the bacterium's extracellular proliferation during early or , with in vitro data confirming susceptibility to these agents via minimal inhibitory concentrations (MICs) typically below clinical breakpoints. Following stabilization, transition to an oral eradication phase with TMP-SMX, sometimes augmented by or other agents like , is standard to combat intracellular persistence within macrophages, where the pathogen forms biofilms and evades host immunity. Therapy duration extends at minimum 10-14 days intravenously for the intensive phase in mild cases, but often 2-8 weeks or longer in severe or disseminated forms, followed by 3-12 months of oral maintenance to prevent relapse from dormant intracellular reservoirs. Historical case reports and accidental exposures demonstrate efficacy of sulfonamides like sulfadiazine combined with trimethoprim in resolving chronic nodules or abscesses, though modern protocols favor TMP-SMX due to broader intracellular penetration and supporting murine models of glanders clearance. Alternatives for intolerance or resistance include quinolones (e.g., ) or , selected based on testing, as B. mallei exhibits variable susceptibility to penicillins, aminoglycosides, and first-generation cephalosporins. Susceptibility testing via or disk diffusion is essential prior to and during , given reports of resistance emergence in laboratory-adapted strains and the pathogen's capacity for efflux pumps and production, which can reduce against persistent forms. Empirical regimens assume wild-type , but mitigates selection pressure, with evidence from human cases showing clearance only after addressing both extracellular and intracellular niches through extended exposure.

Therapeutic Challenges and Outcomes

Glanders in humans remains highly lethal, with untreated acute septicemic cases exhibiting a of 95%, often resulting in death within 7-10 days of symptom onset. Chronic forms carry an untreated fatality rate of approximately 50%, reflecting the disease's capacity for latency and sporadic progression. Even with intervention, overall survival rates hover at 40-60%, frequently accompanied by debilitating long-term sequelae including cutaneous scarring, deformities, and pulmonary . Key therapeutic obstacles stem from Burkholderia mallei's biological adaptations, such as intracellular persistence within host macrophages, which shields the pathogen from antibiotics and fosters chronic infection. formation further exacerbates resistance by impeding drug penetration and promoting bacterial survival post-treatment. The infrequency of human infections—fewer than 30 documented cases since 2000—precludes establishment of standardized protocols, leading to reliance on empirical regimens adapted from management, with variable efficacy. Relapse risks persist even after apparent , attributable to dormant bacterial reservoirs that reactivate months or years later, necessitating extended and potentially indefinite in survivors. A 2024 case in northeastern involved a 73-year-old hospitalized for glanders, who underwent molecular-confirmed and intensive , demonstrating survival potential under aggressive intervention but underscoring the disease's unpredictable course. In contrast, equine cases typically culminate in due to intractable chronicity and zoonotic hazards, with no viable curative options beyond . These outcomes highlight glanders' resistance to full eradication, countering notions of straightforward curability despite advances in supportive .

Prevention and Control

Animal Management Strategies

Mandatory reporting of suspected glanders cases is required under World Organisation for Animal Health (WOAH) standards, as the disease is listed among notifiable equine infections, enabling coordinated international surveillance and response. Primary control measures emphasize of exposed herds, immediate of animals testing positive via intradermal mallein or complement fixation tests, and disinfection of contaminated premises using agents effective against , such as or chlorine-based solutions. These test-and-slaughter protocols, without reliance on due to diagnostic interference risks, have proven effective in preventing reservoir establishment, as infected equids serve as the sole with potential for carriage. Surveillance in endemic regions, such as parts of and the , relies on periodic serological screening of equids using or agglutination tests to identify subclinical infections, supplemented by clinical for nasal , nodules, or . In historically affected areas like the , systematic implementation of these measures led to eradication by the early 1940s, with the last confirmed animal cases traced to 1934 following aggressive depopulation of positives and movement restrictions. Similar programs eradicated the disease in by 1939 through federal testing mandates and compensation for culled animals, demonstrating the feasibility of elimination via sustained, resource-intensive enforcement. Economic trade-offs pose challenges in resource-limited settings, where the value of working equids incentivizes incomplete disclosure of positives, hindering full eradication despite WOAH guidelines; for instance, in , ongoing from 2006–2018 detected cases across multiple states but highlighted gaps in rural reporting tied to dependencies. This underreporting perpetuates endemicity, as partial fails to eliminate environmental fomites or undetected carriers, underscoring the causal link between rigor and persistence absent viable alternatives like vaccines.

Vaccine Research and Development

No licensed vaccine exists for preventing glanders in humans or animals as of October 2025. Efforts to develop effective immunizations have focused primarily on preclinical models due to the pathogen's classification as a select agent and its potential as a bioweapon, with challenges including Burkholderia mallei's intracellular lifestyle, immune evasion mechanisms, and the need for robust mucosal and cell-mediated immunity to counter aerosol or intranasal infection routes. Historical live-attenuated strains, such as the ΔtonB Δhcp1 mutant designated CLH001, have demonstrated immunogenicity and protection in murine models; for instance, immunization of BALB/c mice with CLH001 resulted in 100% survival following lethal intranasal or aerosol challenges with B. mallei ATCC 23344, alongside elevated IgG titers and T-cell responses. However, efficacy remains unproven in equines—the primary reservoir—and larger animals, with attenuation strategies risking residual virulence or incomplete strain coverage. Recent research emphasizes subunit and glycoconjugate vaccine candidates, often leveraging cross-protection from () platforms due to antigenic similarities between the species. Glycoconjugate approaches targeting (LPS) O-antigens have shown partial efficacy in mice against heterologous B. mallei strains, but glanders-specific hurdles persist, including LPS heterogeneity across isolates and suboptimal protection against chronic dissemination. For example, subunit vaccines incorporating outer membrane proteins or alkyl hydroperoxide reductase have elicited responses in , yet clinical translation lags owing to inconsistent aerosol challenge outcomes and the absence of correlates of protection validated in relevant models. No candidates have advanced to trials for glanders alone, though melioidosis-focused subunit vaccines are approaching I testing, with potential dual-use evaluated under priorities. United States Department of Defense (DoD)-funded initiatives drive much of the current pipeline, prioritizing single-dose formulations for military against aerosolized threats. In 2023, VitriVax received a DoD contract to develop a thermostable, single-shot targeting both and glanders via prime-boost strategies, building on attenuated vectors like live vaccine strains (LVS) modified for safety. Empirical data underscore persistent gaps: while mouse survival rates exceed 80% in optimized regimens, scalability to equines or reveals attenuation trade-offs, such as reduced T-cell priming against hypervirulent strains, necessitating adjuncts like adjuvants for mucosal delivery. Overall, development remains stalled by the lack of standardized equine endpoints and regulatory pathways for animal pathogens.

Historical Context

Pre-Modern Occurrences

Glanders was first described in texts as a of horses characterized by nasal discharge, ulcers, and nodules. (c. 460–370 BC) referenced symptoms consistent with the condition, including farcy-like lesions in equines. (384–322 BC) similarly documented equine infections involving glandular swellings and respiratory issues, attributing them to environmental and dietary factors. These early accounts established glanders as a persistent scourge in horse-dependent societies, where trade routes and military campaigns facilitated spread among herds. By , Roman sources provided clearer insights into its contagious nature. The historian , writing in the 5th century AD, explicitly described glanders () as transmissible between horses via shared feed, water, or contact, recommending isolation of affected animals—the earliest documented recognition of its . This understanding persisted through medieval , where glanders outbreaks ravaged during conflicts like the , linking the disease's persistence to the mass movement of equines in warfare and commerce. In the 18th and 19th centuries, glanders epidemics intensified in and amid expanding equine use in armies and trade. Dense stabling of horses in military camps accelerated transmission, with outbreaks decimating up to 20–30% of mounts in some campaigns, as reported in veterinary records from and . For instance, during the (1799–1815), glanders contributed to equine losses exceeding tens of thousands across European forces, exacerbating supply chain disruptions tied to overland troop movements. Similar patterns afflicted U.S. armies in the early 19th century, where frontier trade and militia mobilizations triggered herd-wide infections, underscoring causal ties to human-facilitated equine congregation. Human cases emerged as evidence of zoonotic , primarily among handlers exposed via cuts or during grooming and farriery. By the late , clinicians noted parallel symptoms in stable workers—fever, skin nodules, and pulmonary involvement—linking them directly to infected , though systematic confirmation awaited 19th-century bacteriological advances. This occupational pattern reinforced glanders' role as a veterinary-public threat, with mortality in untreated human infections approaching 95%, prompting early measures in endemic regions.

Military Exploitation in Warfare

During , Imperial Germany's Kulturabteilung orchestrated a biological sabotage campaign using to target Allied horses and mules critical for logistics. German agents, including Anton Dilger operating from a makeshift laboratory in , cultured the bacterium and infected equines at ports such as , and in South American neutral countries like . Infections were introduced via contaminated feed or direct inoculation, leading to outbreaks that killed thousands of animals before they reached European fronts. In the lead-up to and during , the and researched glanders for defensive and offensive applications, including studies on and animal at facilities like Camp Detrick, but no operational deployment against enemies occurred. Soviet biological programs similarly weaponized B. mallei, classifying it as an operational agent and producing over 2,000 tons of dry agent in a single year during the , though Soviet accusations of U.S. or Allied use lacked verifiable evidence. Post-World War II, the 1972 banned the development, production, and stockpiling of agents like B. mallei for warfare, entering into force in 1975. Despite ratification by major powers, covert programs persisted, with Soviet efforts continuing in violation of the treaty until the program's partial dismantlement in the , as confirmed by defector accounts and declassified intelligence. No empirical records confirm glanders deployment in subsequent conflicts.

Biosecurity Implications

Bioterrorism Potential

Burkholderia mallei, the causative agent of glanders, is classified by the Centers for Disease Control and Prevention (CDC) as a Category B agent, indicating moderate ease of dissemination and potential for moderate-to-high morbidity and mortality. This classification stems from its ability to be produced in laboratories using standard microbiological techniques, as the bacterium can be cultured on common media despite being an . Its stability in form facilitates as a primary route of , with documented laboratory exposures confirming aerosol transmission risks. Untreated human infections often result in high lethality, approaching 95% for septicemic forms, while equine hosts exhibit similar severe outcomes, amplifying zoonotic dissemination potential. As a select agent under U.S. regulations, B. mallei access is tightly controlled through registration, security, and transfer restrictions enforced by the CDC and USDA, mitigating unauthorized acquisition. However, dual-use research of concern (DURC) involving attenuated strains, such as the CLH001 candidate, introduces risks; manipulations intended to reduce could inadvertently enhance transmissibility or be reversed for weaponization if protocols lapse. Such research, while advancing countermeasures, necessitates rigorous oversight to prevent misuse, as B. mallei falls under federal DURC policies for life sciences experiments with or bioweapon potential. Countermeasures include antibiotics like or , which are stockpiled in the for threats, though efficacy diminishes in advanced disease stages. No licensed human or veterinary exists, despite historical attempts, leaving populations vulnerable to intentional release. Modeling studies for related species suggest urban outbreaks could propagate via contaminated water sources or aerosols, with and routes enabling focal spread in high-density areas before , though limited person-to-person curbs .

Modern Surveillance and Response

The (WOAH) establishes standards for glanders surveillance, requiring member countries to monitor susceptible equid populations, report all suspected cases immediately, and implement identification followed by humane of infected animals to prevent . These protocols, combined with serological testing for import/export controls, have enabled eradication in regions with stringent enforcement, such as , where no cases have been reported since 1962. In contrast, lax implementation correlates with persistence and re-emergence; , for instance, reports annual cases across multiple states, resulting in export bans on live equids and semen that disrupt and equine industries. Contemporary outbreak responses leverage molecular tools, including whole-genome sequencing and multi-locus analysis (MLVA), to genotype Burkholderia mallei strains and trace transmission chains rapidly. For example, sequencing of Pakistani isolates from 1999–2020 identified distinct , facilitating epidemiological linkage during surveillance-driven detections. measures, such as WOAH-guided and bans on importing equids from endemic areas, further mitigate risks, as evidenced by heightened restrictions following outbreaks in and that impacted global equine transport. The U.S. Centers for Disease Control and Prevention (CDC) supports zoonotic vigilance through diagnostic confirmation and molecular typing, emphasizing integration with animal health reporting to detect human spillover early. Persistent challenges include underreporting in , where inadequate and reliance on passive detection allow silent circulation; between 2020 and 2025, confirmed equine cases in and , alongside serological surveys revealing higher prevalence, underscore gaps despite mandatory notifications. Global trade in equids exacerbates spread potential, with undetected carriers bypassing controls, while climate factors like expanded equid ranges in warmer regions may indirectly facilitate vector or environmental persistence, though direct causation remains unquantified. Effective programs thus prioritize active serological screening and cross-border to address these disparities.

References

  1. [1]
    Glanders and Melioidosis - StatPearls - NCBI Bookshelf - NIH
    Aug 14, 2023 · Glanders is an infectious disease caused by Burkholderia mallei, a gram-negative aerobic nonmotile bacterium. Melioidosis is an infectious ...Continuing Education Activity · History and Physical · Treatment / Management
  2. [2]
    [PDF] Glanders is a contagious and fatal disease of horses, donkeys, and ...
    Description and importance of the disease: Glanders is a contagious and fatal disease of horses, donkeys, and mules, caused by infection with the bacterium ...
  3. [3]
    Etymologia: Glanders - Volume 21, Number 1—January 2015 - CDC
    Glanders is caused by Burkholderia mallei and is communicable to humans but should not be confused with human melioidosis, caused by Burkholderia pseudomallei.
  4. [4]
    Glanders Fact Sheet - New York State Department of Health
    Glanders is an infectious disease caused by the bacterium Burkholderia mallei. Glanders is primarily a disease affecting horses, but it also affects donkeys, ...Missing: definition | Show results with:definition
  5. [5]
    Glanders: an overview of infection in humans - PMC - PubMed Central
    Sep 3, 2013 · It was first described by the Greeks in 450–425 BC and again by the Romans in 400–500 AD. Throughout history glanders has been known by other ...
  6. [6]
    Clinical and Molecular Characterization of Human Burkholderia ...
    Oct 19, 2024 · Burkholderia mallei is a gram-negative bacterium that causes glanders disease, which primarily affects equids. B. mallei can infect humans and ...
  7. [7]
    Laboratory-Acquired Human Glanders --- Maryland, May 2000 - CDC
    ... Burkholderia mallei, the causative agent of glanders. This report summarizes the first human case of glanders in the United States since 1945, and ...
  8. [8]
    Molecular Typing of Burkholderia mallei Isolates from Equids ... - CDC
    May 6, 2021 · Burkholderia mallei is the etiologic agent of the contagious and fatal infection in equids known as glanders. It is one of the most ancient ...
  9. [9]
    Glanders in Horses and Other Equids - Generalized Conditions
    Glanders is a contagious, often fatal, zoonotic disease that primarily affects horses and other equids. It is caused by the bacterium Burkholderia mallei.
  10. [10]
    Glanders: An ancient and emergent disease with no vaccine or ... - NIH
    Jun 11, 2025 · One of the most devastating outbreaks occurred at the Federal Army's largest horse supply depot, Giesboro, in 1864. Infected horses sold to the ...
  11. [11]
    Structural flexibility in the Burkholderia mallei genome - PMC - NIH
    Genome Features. The genome of B. mallei consists of two circular chromosomes. Chromosome 1 contains 3,510,148 bp, and chromosome 2 contains 2,325,379 bp. A ...
  12. [12]
    Structural flexibility in the Burkholderia mallei genome - PNAS
    The complete genome sequence of Burkholderia mallei ATCC 23344 provides insight into this highly infectious bacterium's pathogenicity and evolutionary history.
  13. [13]
    Burkholderia mallei - an overview | ScienceDirect Topics
    Burkholderia mallei is the causative agent of glanders, a disease primarily affecting horses and donkeys. In contrast to B. pseudomallei, B. mallei does not ...
  14. [14]
    Burkholderia mallei: Infectious substances Pathogen Safety Data ...
    Mar 9, 2023 · In humans, acute glanders has a typical incubation period of 1-14 days, while chronic glanders has an incubation period of up to 12 weeks.
  15. [15]
    A Type IV Pilin, PilA, Contributes to Adherence of Burkholderia ...
    A pilA deletion mutant has reduced adherence to human epithelial cells and is less virulent in the nematode model of virulence and the murine model of ...
  16. [16]
  17. [17]
  18. [18]
  19. [19]
  20. [20]
    Glanders - WOAH - World Organisation for Animal Health
    Glanders is an infectious and life-threatening disease that mainly affects horses, donkeys or mules caused by the bacterium Burkholderia mallei.
  21. [21]
    Glanders | School of Veterinary Medicine
    Feb 18, 2020 · Glanders is a contagious disease caused by the bacterium Burkholderia mallei. Infection can result in pus-forming lesions on the skin and respiratory ...Missing: transmission | Show results with:transmission
  22. [22]
    Glanders | Equine Disease Communication Center
    Begins with high fever, poor appetite, difficult breathing and coughing · A highly infectious, thick, yellowish-green nasal discharge · Thick crusty eye discharge ...
  23. [23]
    [PDF] Glanders - CFSPH
    Aug 7, 2025 · One old description of large outbreaks among mules also reported that, several days before the onset of other clinical signs, many mules ...
  24. [24]
  25. [25]
    Spatiotemporal Analysis of Glanders in Brazil - ScienceDirect.com
    Each year, glanders cases are reported in several regions of the country, causing severe economic losses and trade restrictions. The present study describes and ...Missing: Mongolia | Show results with:Mongolia
  26. [26]
    Current status of glanders in Brazil: recent advances and challenges
    Aug 7, 2025 · Glanders is an infectious disease that causes serious damage to the equine production chain in countries where it occurs endemically and ...
  27. [27]
    Case Report Histopathological and diagnostic aspects of glanders ...
    Glanders is a zoonotic disease of equids caused by the bacterium Burkholderia mallei, responsible for considerable economic loss.Missing: obligate parasite
  28. [28]
    The Socioeconomic Impact of Diseases of Working Equids in Low ...
    Working equids provide a crucial contribution to the livelihoods and food security of communities in low- and middle-income countries (LMICs).
  29. [29]
    How glanders impacts on brick kiln communities - Brooke
    It's estimated that during the brick kiln season, 15 families can earn up to $16,581 in total. Based on interviews with owners, estimated earnings after a ...
  30. [30]
    Glanders: An ancient and emergent disease with no vaccine or ...
    Jun 11, 2025 · Despite the low incidence of animal-to-human transmission, occupational exposure of the animal handlers remains a key risk factor, particularly ...
  31. [31]
    Glanders - Illinois Department of Public Health
    Cutaneous infection (skin): A patient will have swelling and sores at the site of the skin infection. The person also may have swollen lymph nodes.
  32. [32]
    Glanders: an overview of infection in humans
    Sep 3, 2013 · Time between exposure and symptoms​​ The acute form of disease has a typical incubation period of 1–14 days[25], while the chronic form of the ...
  33. [33]
    Clinical and Molecular Characterization of Human Burkholderia ...
    We report a case of Burkholderia mallei causing glanders in a 73-year-old patient from the Northeast Region of Brazil. The patient was hospitalized with ...
  34. [34]
    Melioidosis and glanders - DermNet
    The two diseases differ in their geographical spread and ecology. What is melioidosis? Melioidosis is an uncommon tropical disease caused by the bacterium, ...
  35. [35]
    [PDF] Chapter 8 GLANDERS
    Given the recent outbreaks in horses, donkeys, and dromedaries in some regions of India,. Bahrain, Brazil, Lebanon, Pakistan, and the United. Arab Emirates, ...
  36. [36]
    [PDF] Burkholderia mallei (Glanders) and Burkholderia pseudomallei ...
    Oct 19, 2011 · Glanders is caused by infection with the bacterium Burkholderia mallei, and melioidosis is caused by Burkholderia pseudomallei. Both have the ...
  37. [37]
    AAEP Publishes Glanders Guidelines
    “Although Glanders was officially eradicated in the United States in 1934, it continues to be present in many countries throughout the world,” said Dr. Sage, ...
  38. [38]
    Spread analysis of glanders in the state of Piauí, northeastern Brazil
    The present study aimed to evaluate the spatial and temporal distribution of official cases of glanders in Piauí between 2015 and 2022.
  39. [39]
    Brazil Continues Battle Against Glanders As Olympic Events Approach
    Jul 27, 2016 · Some 623 horses were euthanized between 2013 and 2015 because they were suspected to have glanders, although some Brazilians say the disease ...
  40. [40]
    Seroprevalence of equine glanders in horses in the central and ...
    Public awareness of the presence of glanders among horses, with an emphasis on its economic impact and public health implications, is hereby strongly ...
  41. [41]
    First glanders cases detected in Nepal underscore the need for ...
    Apr 6, 2022 · Several outbreaks of glanders in equids have been recently reported in South Asia, the Middle East, and South America (Brazil) [2].
  42. [42]
    Weqaa Officially Declares Kingdom Free of Glanders
    Sep 14, 2025 · ... 2025, SPA -- The World Organization for Animal Health (WOAH) has officially recognized the Kingdom of Saudi Arabia as free of glanders ...
  43. [43]
    Current status of glanders in Brazil: recent advances and challenges
    Aug 31, 2022 · This study aimed to conduct an integrative review of the advances in the knowledge of glanders in Brazil over the last three decades since its re-emergence.
  44. [44]
    Glanders – Epidemiology - Virginia Department of Health
    Aug 6, 2025 · Common symptoms of glanders include fever with chills, muscle aches, chest pain, muscle tightness, and headache. Other symptoms may include ...
  45. [45]
    Glanders in - AVMA Journals
    Aug 15, 2008 · Glanders is uncommon in humans, but it is painful and life threatening; the mortality rate among untreated clinical cases is high. Persons with ...
  46. [46]
    A novel selective medium for the isolation of Burkholderia mallei ...
    May 7, 2019 · In this study, we developed a new selective medium (Burkholderia mallei agar: BM agar) for laboratory diagnosis of glanders and compared its ...
  47. [47]
    Systematic monitoring of glanders-infected horses by complement ...
    Burkholderia mallei was identified by biochemical protocol assessing catalase, oxidase, indole, nitrate reduction, results of the Voges-Proskauer test, motility ...
  48. [48]
    Handling Burkholderia pseudomallei Isolates without a Biosafety ...
    Jun 18, 2021 · These guidelines suggest handling of the organism in a biosafety level 3 (BSL3) facility within a class II biological safety cabinet (BSC). This ...
  49. [49]
    Using real-time PCR to specifically detect Burkholderia mallei
    This investigation provides two real-time PCR assays for the rapid and specific identification of B. mallei.
  50. [50]
    Use of a Recombinant Burkholderia Intracellular Motility A Protein ...
    ... PCR ... glanders antibodies with high sensitivity and specificity. We describe here a novel recombinant BimA protein for the diagnosis of equine glanders.
  51. [51]
    A genetic variant of Burkholderia mallei detected in Kuwait ...
    Aug 15, 2020 · This study leads to recommendations regarding the use of PCR systems for the molecular diagnosis of glanders, especially in regions where the circulating B. ...
  52. [52]
    Systematic monitoring of glanders-infected horses by complement ...
    Oct 6, 2020 · A modified PCR protocol improved the diagnostic sensibility for glanders. Horses with chronic glanders disease may show false negative serology results.Missing: strangles | Show results with:strangles
  53. [53]
    [PDF] GLANDERS AND MELIOIDOSIS - WOAH
    It is a zoonotic disease and has been known since ancient times. It is caused by the bacterium Burkholderia mallei (Yabuuchi et al., 1992) and has been ...
  54. [54]
    Evaluation of the comparative accuracy of the complement fixation ...
    Apr 5, 2019 · Glanders is a zoonotic contagious disease of equids caused by Burkholderia (B.) mallei. Serodiagnosis of the disease is challenging because ...
  55. [55]
    Performance of MALDI-TOF MS, real-time PCR, antigen detection ...
    Sep 5, 2024 · MALDI-TOF MS had a sensitivity of 1.0 and specificity of 1.0 for the identification and differentiation of B. pseudomallei from related Burkholderia species.
  56. [56]
    Assessment of the control measures of the category A diseases of ...
    Jan 12, 2022 · A genetic variant of Burkholderia mallei detected in Kuwait: consequences for the PCR diagnosis of glanders. Transboundary and Emerging ...
  57. [57]
    Workshop on Treatment of and Postexposure Prophylaxis for ... - CDC
    Nov 6, 2012 · For postexposure prophylaxis, recommended drugs are trimethoprim/sulfamethoxazole or co-amoxiclav. To improve the timely diagnosis of ...Missing: sulfonamides | Show results with:sulfonamides
  58. [58]
    In Vitro Susceptibilities of Burkholderia mallei in Comparison to ...
    The antibiotic susceptibility of B. mallei was similar to that of B. pseudomallei, with resistance to a number of antibiotics (Table 1). All strains of both ...
  59. [59]
    [PDF] VDH Glanders: Guidance for Healthcare Providers
    May 31, 2023 · Treatment of both glanders and melioidosis consists of an intensive phase with intravenous therapy lasting for at least 10–14 days (Table 2) ...
  60. [60]
    Biofilm Targeting Strategy in the Eradication of Burkholderia Infections
    Jun 18, 2021 · This review aims to describe the capacity of Burkholderia to form a biofilm, the regulation of its biofilm formation, the efficacy of antibiotics to eradicate ...
  61. [61]
    Glanders - an overview | ScienceDirect Topics
    The normal incubation period for human disease is 10–14 days. Major symptoms. The symptoms and signs of glanders depend upon the mechanism of exposure. They ...
  62. [62]
    Glanders, the rare infectious disease that's also a deadly biological ...
    Nov 21, 2023 · In humans, glanders is 95% fatal without treatment. With treatment, the mortality rate drops to 50%, which is still a high percentage.
  63. [63]
    [PDF] glanders - WOAH
    Jun 17, 2024 · Glanders in humans is a rare but potentially fatal disease. For the purposes of the Terrestrial Code, glanders is defined as an infection of ...
  64. [64]
    Glanders - an overview | ScienceDirect Topics
    Control Strategies​​ Glanders has been successfully eliminated from many countries through the slaughter of animals with a positive mallein test. A wide variety ...Missing: eradication | Show results with:eradication
  65. [65]
    Serological surveillance and clinical investigation of glanders ...
    Jan 9, 2020 · With regard to the month-wise occurrence of glanders, highest prevalence rate was recorded in May and June (Table 4), whereas highest number of ...
  66. [66]
    The eradication of glanders in Canada - PMC - NIH
    Eradication of glanders in the United States in 1934 eliminated the risk of importing the infection, and this no doubt contributed to the eradication of ...
  67. [67]
    Knowledge, awareness and perception about equine glanders ...
    Mar 14, 2024 · In India, glanders re-emerged in 2006 and thereafter regular outbreaks have been reported in various states (n = 14). Frequent and prolonged ...
  68. [68]
    [PDF] Glanders: Historical military use and potential bioterrorism concern
    Sep 30, 2025 · Glanders is reported to be endemic in horses ... Serological and bacteriological surveillance of glanders among horses in Central Region of Iran.
  69. [69]
    Burkholderia pseudomallei and Burkholderia mallei vaccines
    An efficacious melioidosis/glanders vaccine would ideally provide high level protection against multiple routes of infection, protect against multiple LPS ...Missing: research | Show results with:research
  70. [70]
    Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live ...
    Jul 15, 2019 · We found that CLH001-immunized mice showed 100% survival against intranasal and aerosol challenge with B. mallei ATCC 23344. Moreover, this ...
  71. [71]
    Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live ...
    Jul 15, 2019 · Most glanders and melioidosis vaccine candidates developed today have been tested using two common mouse strains, BALB/c and C57BL/6 [20,21,22].
  72. [72]
    Development of Melioidosis Subunit Vaccines Using an ...
    In the present study, we investigated the immunogenicity and protective capacity of B. pseudomallei alkyl hydroperoxide reductase subunit C (AhpC) when ...
  73. [73]
    Evaluation of highly conserved Burkholderia pseudomallei outer ...
    Aug 6, 2025 · Currently, two vaccines are considered leading candidates to prevent melioidosis and are nearing human clinical trials: a subunit vaccine ...
  74. [74]
    VitriVax Wins DoD Contract to Develop Single-Shot Vaccine for ...
    Jul 19, 2023 · VitriVax Wins DoD Contract to Develop Single-Shot Vaccine for Melioidosis and Glanders ... Subscribe to Global Biodefense. Get the latest news on ...Missing: funding | Show results with:funding
  75. [75]
    LVS ΔcapB-vectored multiantigenic melioidosis vaccines protect ...
    Mar 21, 2024 · We describe a safe and potent melioidosis vaccine that protects against lethal respiratory challenge with B. pseudomallei in a highly sensitive small animal ...
  76. [76]
    Vaccines for the Prevention of Melioidosis and Glanders - PMC - NIH
    This review will outline recent vaccine strategies to prevent infections by B. pseudomallei, and B. mallei, highlighting potential candidate vaccines.
  77. [77]
    GLANDERS - Cambridge University Press & Assessment
    6 Nevertheless, there can be littledoubt that losses through glanders in all the major wars in Europe and elsewhere, from the Crusades and throughout the ...Missing: 19th | Show results with:19th<|control11|><|separator|>
  78. [78]
    Glanders: An emerging threat revisite
    It was a significant concern during the 18th and 19th centuries when armies relied heavily on horses for transportation and warfare. The disease was known for ...
  79. [79]
    Glanders - an overview | ScienceDirect Topics
    Glanders was described by Hippocrates and has long been recognized as an occupational risk for horse handlers, veterinarians, equine butchers, and laboratory ...
  80. [80]
    “Tony's Lab” | National Archives
    May 12, 2025 · Germ Warfare in WWI Used on Horses ... According to later estimates, the German germ sabotage campaign in America killed thousands of horses ...
  81. [81]
    First shots fired in biological warfare - Nature
    Sep 17, 1998 · The bacteria used were those that cause anthrax and glanders,. Germany's programme of biological sabotage began in 1915, with a series of ...
  82. [82]
    Instances of Biowarfare in World War I (1914–1918) - PubMed Central
    Apr 29, 2024 · Glanders would serve as a primary biological weapon until the mechanization of armies, which eventually led to the replacement of animals, ...
  83. [83]
    Scientists and the history of biological weapons: A brief historical ...
    After the First World War, France, the UK, the USA and the Soviet Union all suspected that the defeated Germany was secretly developing biological weapons to ...
  84. [84]
    History of Biological Weapons - A.T. Still University
    Jun 14, 2011 · In WWI from 1915-1918 the Germans used biological agents to attempt to cause severe disease (glanders and anthrax) in the horses and mules used ...
  85. [85]
    [PDF] NPR 6.3: BIOLOGICAL WEAPONS IN THE FORMER SOVIET UNION
    The final list included smallpox and plague as strategic weapons; tularemia, glanders, and VEE as operational weapons; and anthrax and Marburg virus as ...
  86. [86]
    Biological Weapons Convention (BWC)
    The BTWC mandates the elimination of existing biological weapons and prohibits developing, stockpiling or using biological and toxin weapons.
  87. [87]
    [PDF] The Soviet Biological Weapons Program and Its Legacy in Today's ...
    Biological warfare was not waged on the Eastern Front during World War I,9 but with Russian troops having experienced the full effects of German chemical.
  88. [88]
    Antimicrobial Drug–Selection Markers for Burkholderia ...
    B. pseudomallei and B. mallei are 2 closely related select agents that cause melioidosis and glanders, respectively. B. mallei causes natural glanders, a rare ...
  89. [89]
    Management of Accidental Laboratory Exposure to Burkholderia ...
    Glanders is a disease of equines caused by Burkholderia mallei, which appears to be a clone of B. pseudomallei that has lost genetic material in association ...
  90. [90]
    Select Agents and Toxins List
    Overlap Select Agents and Toxins · Bacillus anthracis · Burkholderia mallei · Burkholderia pseudomallei · Nipah virus · Venezuelan equine encephalitis virus [4] ...
  91. [91]
    Burkholderia mallei CLH001 Attenuated Vaccine Strain Is ...
    Jul 21, 2016 · Here we show that CLH001 is attenuated, safe, and effective at protecting against lethal B. mallei challenge. Intranasal administration of ...Missing: risks | Show results with:risks
  92. [92]
    Dual Use Research of Concern (DURC) - UCSD Blink
    Nov 21, 2023 · Research involving any quantity of botulinum neurotoxin should be evaluated for DURC potential.) Burkholderia mallei; Burkholderia pseudomallei ...
  93. [93]
    [PDF] Implementation Guidance for the United States Government Policy ...
    May 6, 2024 · Step 4, proceed to Step 6 to assess dual use risks and determine whether the research should be designated as Category 1 research. • If NONE ...
  94. [94]
    Research to Support Countermeasures for Melioidosis - FDA
    Feb 25, 2021 · This project will examine a previously unstudied route of melioidosis infection (ingestion), and assess the pharmacokinetics (PK)—how drugs move ...Missing: stockpiled urban
  95. [95]
    HHS awards grant for antibiotic to fight melioidosis, glanders - CIDRAP
    Jun 25, 2013 · ... glanders, which are classified as potential bioterrorism threats. The contract was awarded to Basilea Pharmaceutica Ltd., based in Basel ...
  96. [96]
    Spatiotemporal Analysis of Glanders in Brazil - PubMed
    Each year, glanders cases are reported in several regions of the country, causing severe economic losses and trade restrictions. The present study describes ...Missing: disruptions | Show results with:disruptions
  97. [97]
    [DOC] Review of risks associated with glanders (Burkholderia mallei) in ...
    The illegal movement of horses across borders has been linked to glanders outbreaks, highlighting the importance of border control measures. In 2021, Nepal ...Missing: equids | Show results with:equids
  98. [98]
    Sequencing-Based Genotyping of Pakistani Burkholderia mallei ...
    May 24, 2022 · The genomes of 19 B. mallei strains isolated between 1999 and 2020 in different locations were sequenced and their genotypes were determined.
  99. [99]
    Genotyping of Burkholderia mallei from an Outbreak of Glanders in ...
    In recent years, several outbreaks of glanders occurred in the horse populations in Asia, Middle-East (Afghanistan, Kuwait, Iran, Iraq, Pakistan, Syria), Africa ...
  100. [100]
    Glanders and the risk for its introduction through the international ...
    Jun 11, 2016 · False positives are problematic for the horse-owner and veterinary authority, whereas false negatives may allow the reintroduction of B.Missing: limitations | Show results with:limitations
  101. [101]
    One Health surveillance approaches for melioidosis and glanders
    Dec 15, 2022 · However, glanders cases continue to crop up regularly throughout Asia, Africa, South and Central America, and the Middle East. Melioidosis and ...